Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Trastuzumab Deruxtecan Slated for Study in HER2+ Gastric/GEJ Cancer

February 15th 2021

Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.

Dr. Grothey on Potential Combinations With Trastuzumab Deruxtecan in GI Malignancies

February 11th 2021

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology

February 8th 2021

Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.

TheraSphere Shows Efficacy, Limited Toxicity, and Potential Synergy With Immunotherapy in HCC

February 8th 2021

Yttrium-90 glass microspheres, a personalized radiotherapeutic cancer treatment, induced an overall response rate of 72.2% per blinded independent central review as neoadjuvant or stand-alone treatment in 143 evaluable patients with unresectable hepatocellular carcinoma.

Open Questions and Future Directions in mCRC

February 4th 2021

Experts in CRC discuss questions and management of mCRC.

Using Molecular Testing to Guide Treatment Selection in mCRC

February 4th 2021

John Marshall, MD, and Axel Grothey, MD, discuss how molecular testing results guide treatment decisions in patients with mCRC.

Drive-By Flu-FIT Program May Address CRC Screening Decline in Diverse Communities Amidst COVID-19 Crisis

February 3rd 2021

February 3, 2021 - The Drive-By Flu-Fecal Immunochemical Test program not only provides safe and socially distanced colorectal cancer screening opportunities during the coronavirus disease 2019 pandemic, but also may help to address screening declines in diverse communities.

Dr. Shitara on Analyzing the Effects of Prior Therapy on TAS-102 in Gastric/GEJ Cancer

February 2nd 2021

Kohei Shitara, MD, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 in patients with metastatic gastric/gastroesophageal junction cancer.

ASCO Names Molecular Profiling in GI Cancers as Advance of the Year

February 2nd 2021

February 2, 2021 - ASCO has chosen molecular profiling driving progress in gastointestinal cancers as its Advance of the Year.

Dr. Ciombor on Sequencing Therapies in Locally Advanced Rectal Cancer

February 2nd 2021

Kristen K. Ciombor, MD, MSCI, discusses sequencing treatment options for patients with locally advanced rectal cancer.

TAS-102 in Third or Fourth Line for mCRC

February 1st 2021

Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.

Regorafenib in Third or Fourth Line for mCRC: Safety in the Re-DOS Trial

February 1st 2021

Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.

Regorafenib in Third or Fourth Line for mCRC: Efficacy in the Re-DOS Trial

February 1st 2021

John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.

Therapy After Progression in mCRC

February 1st 2021

Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.

Redefining BCLC B, Intermediate-Stage HCC: Is There a Role for Combination Systemic Therapy?

January 29th 2021

BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.

Maintenance or Chemo-Free Interval in mCRC

January 29th 2021

Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.

Optimizing First-Line Therapy in mCRC

January 29th 2021

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.

Tislelizumab Prolongs Survival in Advanced, Unresectable, or Metastatic ESCC

January 28th 2021

January 28, 2021 - The anti–PD-1 antibody tislelizumab was found to significantly improve overall survival compared with investigator’s choice of chemotherapy in the treatment of patients with advanced, unresectable, or metastatic esophageal squamous cell carcinoma.

Dr. Marshall on the Emergence of Novel HER2-Targeted Agents in CRC

January 28th 2021

John L. Marshall, MD, discusses the emergence of novel HER2-targeted therapies for patients with colorectal cancer.

Dr. Mody on the Unique Delivery Approach for Y-90 in HCC

January 28th 2021

Kabir Mody, MD, discusses the unique approach used to deliver Y-90 glass microspheres to patients with unresectable hepatocellular carcinoma.